Agreed, the silence is deafening and one can imagi
Post# of 72440
On September 15, 2020 the CEO's 8k and PR highlighted the combination testing of Brilacidin and Remdesivir reducing viral load by 99.85%. About 2 weeks later we heard about the pre-IND meeting with FDA.
Add to this the company's outstanding in vitro results for testing of Brilacidin as a stand alone drug with human lung cell and kidney cell lines over the summer, along with B's previous clinical safety profile across 3 different indications.
Add to this the Sanofi trial manager and the pre-IND meeting request that was granted.
Add to this the urgency of increasing cases in the US and worldwide.
Add to this William DeGrado joining the company as scientific advisor for drug discovery and clinical development.
On Monday Nov. 2, It will be one month since the CEO's last press release and 8k.